PT-141 (Bremelanotida)
Melanocortin receptor agonist (MC4R)
Melanocortin agonist approved for hypoactive sexual desire.
Back to technical sheets- Class
- Melanocortin receptor agonist (MC4R)
- Also known as
- Approved as bremelanotide (e.g. Vyleesi®) for a specific indication
Mechanism of action
Agonist of central melanocortin receptors that modulates pathways involved in sexual desire, through a central (non-vascular) mechanism.
Evidence
Clinical evidence
Clinical evidence: FDA-approved for hypoactive sexual desire disorder in premenopausal women, with controlled trials.
Studied uses
- Hypoactive sexual desire disorder (premenopausal women)
Safety considerations
- Frequent nausea; transient blood-pressure increases
- Contraindicated in uncontrolled hypertension or cardiovascular disease
- Possible hyperpigmentation
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Presentation
- Polvo liofilizado en vial sellado
10 mg Coming soon
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.